Oncoleader | Videos | A New Era of Cancer Therapy Has Begun
Up Next: Don't Underestimate This NK Cell Engager
Video Description
In recent years, immune checkpoint inhibitors have dominated the healthcare landscape. In fact, last year, Merck’s PD-1 mAb KEYTRUDA was the most successful drug in all of medicine. However, a new wave of medicine is on the horizon that is threatening to topple Merck’s oncology kingdom and usurp KEYTRUDA’s throne. Multi-specific protein therapeutics – bispecific antibodies being the most popular.
Video Host
Jeff Martin, PhD
Dr. Jeff Martin is a cancer biologist with a PhD in Cancer Genetics and over a decade of experience in immuno-oncology. As the Founder of Oncoleader, Jeff currently advises biotech professionals, providing expert insights on the best ways to navigate the current trends in the immuno-oncology industry.
